

10/763,105

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 Derwent World Patents Index(R) web-based training during  
August  
NEWS 5 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 6 AUG 30 CA/CAplus -Increased access to 19th century research documents  
NEWS 7 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 8 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 16:39:47 ON 18 SEP 2005

=>

=>

=> FILE REG

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 16:40:13 ON 18 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

10/763,105

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 16 SEP 2005 HIGHEST RN 863378-74-9  
DICTIONARY FILE UPDATES: 16 SEP 2005 HIGHEST RN 863378-74-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:  
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Documents and Settings\VBalasubramania\My Documents\STNEXP4\QUERIES\10763105.str



chain nodes :  
10 11 12 13 14 15 16 22

ring nodes :

1 2 3 4 5 6 7 8 9 23 24 25 26 27 28

chain bonds :  
2-22 4-23 8-10 9-11 13-16 14-15

10/763, 105

```

ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  5-7  6-9  7-8  8-9  23-24  23-28  24-25  25-26  26-27
      27-28
exact/norm bonds :
1-2  1-6  2-3  2-22  3-4  4-5  4-23  5-6  5-7  6-9  7-8  8-9  8-10  9-11  13-16
14-15 23-24 23-28 24-25 25-26 26-27 27-28

```

G1:H, [\*1], [\*2], [\*3]

G2:C,O,S

**Connectivity :**  
12:1 E exact RC ring/chain 13:1 E exact RC ring/chain 14:2 E exact RC ring/chain  
**Match level :**

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:Atom  
24:Atom 25:Atom 26:Atom 27:Atom 28:Atom

## Generic attributes :

10:

Saturation : Unsaturated

11 :

Saturation : Unsaturated


L1 STRUCTURE UPLOADED

=> D L1

L1 HAS NO ANSWERS

L1

1



G1 H, [@1], [@2], [@3]

G2 C.O.S

Structure attributes must be viewed using STN Express query preparation.

10/763, 105

=> S L1 SSS SAM  
SAMPLE SEARCH INITIATED 16:40:39 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 54 TO ITERATE


100.0% PROCESSED 54 ITERATIONS 2 ANSWERS  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 640 TO 1520  
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> D SCAN

L2 2 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-ethylphenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI)  
MF C26 H28 Cl N7 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 2 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Ethanone, 1-[1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-phenyl-4-piperidinyl]- (9CI)  
MF C31 H27 Cl2 N5 O

10/763,105



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> S L1 SSS FUL

FULL SEARCH INITIATED 16:40:54 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1082 TO ITERATE

100.0% PROCESSED 1082 ITERATIONS  
SEARCH TIME: 00.00.01

49 ANSWERS

L3 49 SEA SSS FUL L1

=> FILE CAPLUS

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

FULL ESTIMATED COST

161.33

SESSION

161.54

FILE 'CAPLUS' ENTERED AT 16:41:02 ON 18 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Sep 2005 VOL 143 ISS 13  
FILE LAST UPDATED: 16 Sep 2005 (20050916/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

10/763,105

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> S L3  
L4            2 L3

=> D L4 1-2 BIB HITSTR

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2005:160837 CAPLUS  
DN 142:233372  
TI Pharmaceutical composition using a combination of an opioid receptor antagonist and a CB-1 receptor antagonist for the prevention and treatment of addiction in a mammal  
IN Coe, Jotham Wadsworth; Iredale, Philip A.; McHardy, Stanton Furst; McLean, Stafford  
PA Pfizer Inc, USA  
SO U.S. Pat. Appl. Publ., 25 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005043327	A1	20050224	US 2004-870209	20040617
	WO 2005018645	A1	20050303	WO 2004-IB2596	20040809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-496803P	P	20030821		
IT	736993-30-9	736993-50-3	736993-51-4		
	736993-52-5	736993-53-6	736993-54-7		
	736993-55-8	736993-56-9	736993-57-0		
	736993-58-1	736993-63-8	736993-64-9		
	736993-65-0	736993-66-1	736993-67-2		
	736993-68-3	736993-69-4	736993-70-7		
	736994-31-3	845670-45-3			
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(opioid receptor antagonist-CB-1 receptor antagonist combination for prevention and treatment of addiction)				
RN	736993-30-9	CAPLUS			
CN	2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(methylsulfonyl)-, (1S,4S)-(9CI) (CA INDEX NAME)				

Absolute stereochemistry.




RN 736993-50-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)




RN 736993-51-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-52-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-53-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 736993-54-7 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-55-8 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 736993-56-9 CAPLUS

CN 3-Azetidinecarboxamide, 3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 736993-57-0 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(methylamino)- (9CI) (CA INDEX NAME)




RN 736993-58-1 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 736993-63-8 CAPLUS

CN Ethanone, 1-[1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-phenyl-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 736993-64-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 736993-65-0 CAPLUS

CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 736993-66-1 CAPLUS

CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 736993-67-2 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-methyl- (9CI) (CA INDEX NAME)




RN 736993-68-3 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 736993-69-4 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 736993-70-7 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-6,6-dimethyl- (9CI) (CA INDEX NAME)




RN 736994-31-3 CAPLUS

CN Pyrazolo[1,5-a]-1,3,5-triazine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 845670-45-3 CAPLUS

CN Pyrazolo[1,5-a]-1,3,5-triazine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(1-piperidinyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2004:654773 CAPLUS

DN 141:190806

TI Preparation of pyrazolotriazines as cannabinoid CB<sub>1</sub> receptor antagonists

IN Griffith, David A.

PA Pfizer Inc, USA

SO U.S. Pat. Appl. Publ., 72 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004157839	A1	20040812	US 2004-763105	20040121
	WO 2004069837	A1	20040819	WO 2004-IB269	20040126
	W:	AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KP, KR, KR, KZ, KZ, KZ, LC, LK, LR, LS, LS, LT, LU, LV, MA, MD, MD, MG, MK, MN, MW, MX, MX, MZ, MZ, NA, NI			

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,  
 MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN,  
 GQ, GW, ML, MR, NE, SN, TD, TG

NL 1025404 A1 20040809 NL 2004-1025404 20040204  
 NL 1025404 C2 20050314  
 PRAI US 2003-445728P P 20030206  
 OS MARPAT 141:190806  
 IT 736993-30-9P 736993-35-4P 736993-36-5P  
 736993-37-6P 736993-38-7P 736993-40-1P  
 736993-41-2P 736993-42-3P 736993-43-4P  
 736993-44-5P 736993-45-6P 736993-46-7P  
 736993-47-8P 736993-48-9P 736993-49-0P  
 736993-50-3P 736993-51-4P 736993-52-5P  
 736993-53-6P 736993-54-7P 736993-55-8P  
 736993-56-9P 736993-57-0P 736993-58-1P  
 736993-59-2P 736993-60-5P 736993-61-6P  
 736993-62-7P 736993-63-8P 736993-64-9P  
 736993-65-0P 736993-66-1P 736993-67-2P  
 736993-68-3P 736993-69-4P 736993-70-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (claimed compound; preparation of pyrazolotriazines as cannabinoid CB1  
 receptor antagonists)


RN 736993-30-9 CAPLUS  
 CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-  
 methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(methylsulfonyl)-, (1S,4S)-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 736993-35-4 CAPLUS  
 CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxylic acid, 5-[7-(2-chlorophenyl)-8-  
 (4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-,  
 1,1-dimethylethyl ester, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-36-5 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-37-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-acetyl-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-38-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(2-methyl-1-oxopropyl)-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-40-1 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-benzoyl-5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-41-2 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(ethylsulfonyl)-, (1S,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-42-3 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-[(1-methylethyl)sulfonyl]-, (1S,4S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 736993-43-4 CAPLUS


CN 2,5-Diazabicyclo[2.2.1]heptane-2-sulfonamide, 5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-N,N-dimethyl-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 736993-44-5 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(2,4-dichlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-45-6 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7,8-bis(2-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736993-46-7 CAPLUS


CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-cyanophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



10/763,105


RN 736993-47-8 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-2-methyl-8-(4-methylphenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-48-9 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-ethylphenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-49-0 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-methoxyphenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-50-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(methylamino)- (9CI) (CA INDEX NAME)




RN 736993-51-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-52-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-53-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 736993-54-7 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)




RN 736993-55-8 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 736993-56-9 CAPLUS

CN 3-Azetidinecarboxamide, 3-amino-1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 736993-57-0 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(methylamino)- (9CI) (CA INDEX NAME)




RN 736993-58-1 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)





RN 736993-59-2 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)




RN 736993-60-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)- (9CI)  
(CA INDEX NAME)




RN 736993-61-6 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI)  
(CA INDEX NAME)




RN 736993-62-7 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(methylamino)- (9CI)  
(CA INDEX NAME)




RN 736993-63-8 CAPLUS

CN Ethanone, 1-[1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-phenyl-4-piperidinyl]- (9CI) (CA INDEX NAME)




RN 736993-64-9 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 736993-65-0 CAPLUS

CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 736993-66-1 CAPLUS

CN 4-Piperidinol, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 736993-67-2 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-methyl- (9CI) (CA INDEX NAME)




RN 736993-68-3 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]- (9CI) (CA INDEX NAME)




RN 736993-69-4 CAPLUS

CN 1,3,8-Triazaspiro[4.5]decan-4-one, 8-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 736993-70-7 CAPLUS

CN 2,5,7-Triazaspiro[3.4]octan-8-one, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-6,6-dimethyl- (9CI) (CA INDEX NAME)



IT 736994-23-3P 736994-24-4P 736994-25-5P

736994-26-6P 736994-27-7P 736994-29-9P

736994-30-2P 736994-31-3P 736994-32-4P


736994-33-5P 736994-34-6P 736994-35-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolotriazines as cannabinoid CB1 receptor antagonists)


RN 736994-23-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-fluorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)-, hydrochloride (9CI) (CA INDEX NAME)



RN 736994-24-4 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)-, monohydrochloride (9CI) (CA INDEX NAME)




RN 736994-25-5 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)-, benzenesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 736993-54-7


CMF C24 H23 Cl2 N7 O



CM 2

CRN 98-11-3

CMF C6 H6 O3 S




RN 736994-26-6 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 736993-54-7

CMF C24 H23 Cl2 N7 O




CM 2

CRN 75-75-2  
CMF C H4 O3 S





RN 736994-27-7 CAPLUS  
CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-[(1-methylethyl)amino]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 736994-29-9 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(4-chlorophenyl)pyrazolo[1,5-a]-1,3,5-triazin-4-yl]-4-(ethylamino)-, hydrochloride (9CI) (CA INDEX NAME)




RN 736994-30-2 CAPLUS

CN 3-Azetidinecarboxamide, 1-[7-(2-chlorophenyl)-8-(3-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-3-(ethylamino)- (9CI) (CA INDEX NAME)



RN 736994-31-3 CAPLUS


CN Pyrazolo[1,5-a]-1,3,5-triazine, 7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methyl-4-(4-morpholinyl)- (9CI) (CA INDEX NAME)



RN 736994-32-4 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, dihydrochloride, (1S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 736994-33-5 CAPLUS

CN 3-Azabicyclo[3.1.0]hexan-6-amine, 3-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-, (1 $\alpha$ ,5 $\alpha$ ,6 $\alpha$ )-(9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 736994-34-6 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane, 2-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-5-(ethylsulfonyl)-, dihydrochloride, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 736994-35-7 CAPLUS

CN 2,5-Diazabicyclo[2.2.1]heptane-2-carboxamide, 5-[7-(2-chlorophenyl)-8-(4-chlorophenyl)-2-methylpyrazolo[1,5-a]-1,3,5-triazin-4-yl]-N,N-dimethyl-, (1S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/763,105



=> LOG Y



COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE  
ENTRY  
7.23

TOTAL  
SESSION  
168.77

STN INTERNATIONAL LOGOFF AT 16:41:21 ON 18 SEP 2005



chain nodes :

10 11 12 13 14 15 16 22

ring nodes :

1 2 3 4 5 6 7 8 9 23 24 25 26 27 28

chain bonds :

2-22 4-23 8-10 9-11 13-16 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :

1-2 1-6 2-3 2-22 3-4 4-5 4-23 5-6 5-7 6-9 7-8 8-9 8-10 9-11 13-16 14-15  
23-24 23-28 24-25 25-26 26-27 27-28

G1:H, [\*1], [\*2], [\*3]

G2:C,O,S

Connectivity :

12:1 E exact RC ring/chain 13:1 E exact RC ring/chain 14:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom  
26:Atom 27:Atom 28:Atom



Generic attributes :

10:

Saturation : Unsaturated

11:

Saturation : Unsaturated



chain nodes :

10 11 12 13 14 15 16 22

ring nodes :

1 2 3 4 5 6 7 8 9 23 24 25 26 27 28

chain bonds :

2-22 4-23 8-10 9-11 13-16 14-15

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 23-24 23-28 24-25 25-26 26-27 27-28

exact/norm bonds :

1-2 1-6 2-3 2-22 3-4 4-5 4-23 5-6 5-7 6-9 7-8 8-9 8-10 9-11 13-16 14-15  
23-24 23-28 24-25 25-26 26-27 27-28

G1:H,[\*1],[\*2],[\*3]

G2:C,O,S

Connectivity :

12:1 E exact RC ring/chain 13:1 E exact RC ring/chain 14:2 E exact RC ring/chain

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom  
26:Atom 27:Atom 28:Atom

Generic attributes :

10:

Saturation : Unsaturated

11:

Saturation : Unsaturated